VANCOUVER, British Columbia, Dec. 22, 2023 (GLOBE NEWSWIRE) — Cannabix Technologies Inc. (CSE: BLO) (OTC PINK: BLOZF) (the “Company or Cannabix”), developer of marijuana and alcohol breath testing devices, reports that it will be participating in a “green lab” testing day in Montgomery County, Maryland held by the Montgomery County Police Department. In particular the Company will be supplying its marijuana breathalyzer technology and sending its own representative to facilitate the collection of breath samples alongside law enforcement officers who are testing subjects under the influence of marijuana. The green lab is being held by the Public Safety Training Academy for the Montgomery County Police Department. Various local, regional and out of state representatives are expected to attend the event being held in early January 2024.

The Montgomery County Police Department has held green lab events since 2017, in order to help train police officers about cannabis driving impairment. The green lab aids officers in Advanced Roadside Impaired Driving Enforcement training which helps them learn of the effects of marijuana, and what signs to look for when conducting sobriety tests. Cannabix will be sending its own representative and Breath Collection Units (“BCU”) (See Figure 1) to collect breath samples at various time points pre and post marijuana consumption by subjects. Furthermore, Cannabix will be introducing its technology as a new tool for detection of marijuana in breath to attendees.

In recent months, Cannabix has been using its BCU and Mass Spectrometer Breath Sampler (“MSBS”) to quantify delta-9 THC in human breath samples. Cannabix scientists are using an internal standard to generate a calibration curve for THC quantification in breath samples. Currently, a limit of detection and limit of quantification have been achieved with human subjects in the low picogram range. This allows detection of THC from smoking and edibles up to 4+ hours after consumption.

Cannabix will look to participate in other green labs tests in order to introduce its products to law enforcement stakeholders and collect important data with real world testing conditions.

Fig. 1 Cannabix updated Breath Collection Unit (BCU

About Cannabix Technologies Inc.

Cannabix Technologies Inc. is a developer of marijuana and alcohol breathalyzer technologies for law enforcement, workplaces and laboratories. Cannabix is working to develop delta-9 THC and alcohol screening devices. Delta-9 THC is the psychoactive component of marijuana that causes impairment. Breath testing for delta-9 THC would allow employers and law enforcement to identify recent marijuana use that better aligns with impairment. Cannabix is the developer of contactless breath alcohol detection devices for employers and other settings.

We seek Safe Harbor.

On behalf of the Board of Directors

“Rav Mlait”

CEO
Cannabix Technologies Inc.

For further information, contact the Company at info@cannabixtechnologies.com

The CSE has not reviewed and does not accept responsibility for the adequacy or accuracy of this release.

Cautionary Statement Regarding Forward-Looking Statements

This press release contains forward-looking information that involves various risks and uncertainties regarding future events. Such forward-looking information can include without limitation statements based on current expectations involving a number of risks and uncertainties and are not guarantees of future performance of the Company, such as final development of a commercial or prototype product(s), successful trial or pilot of company technologies, no assurance that commercial sales of any kind actually materialize; no assurance the Company will have sufficient funds to complete product development. There are numerous risks and uncertainties that could cause actual results and the Company’s plans and objectives to differ materially from those expressed in the forward-looking information, including: (i) adverse market conditions; (ii) risks regarding protection of proprietary technology; (iii) the ability of the Company to complete financings; (iv) the ability of the Company to develop and market its future product; and (v) risks regarding government regulation, managing and maintaining growth, the effect of adverse publicity, litigation, competition and other factors which may be identified from time to time in the Company’s public announcements and filings. There is no assurance that its development of breathalyzer technologies will provide any benefit to the Company, and no assurance that any proposed new products will be built, will be successful in beta testing or clinical trials. The is no assurance that the Company will enter into any partnerships to advance any of its corporate initiatives or technologies. There is no assurance that any “patent pending” or “provisional patents” technologies licensed by the Company or owned by the Company will receive patent status by regulatory authorities. The Company is not currently selling commercial breathalyzers. Actual results and future events could differ materially from those anticipated in such information. These and all subsequent written and oral forward-looking information are based on estimates and opinions of management on the dates they are made and are expressly qualified in their entirety by this notice. Except as required by law, the Company does not intend to update these forward-looking statements.

This article was published by CFN Enterprises Inc. (OTCQB: CNFN), owner and operator of CFN Media, the industry’s leading agency and digital financial media network dedicated to the burgeoning CBD and legal cannabis industries. Call +1 (833) 420-CNFN for more information.

About Ryan Allway

Mr. Allway has over a decade of experience in the financial markets as both a private investor and financial journalist. He has been actively involved in the cannabis industry since its inception, covering public and private companies.